This book equips dental care providers with a thorough understanding of the emerging therapies that promise to revolutionize the clinical management of periodontal diseases. Existing therapies targeted to the oral microbiome alone often fail to provide favorable clinical outcomes. Local inflammation and tissue destruction may persist and periodontal tissue regeneration is not predictably achieved. In recognition of these shortcomings, current research efforts are focused on understanding the biological interactions between the host and the resident microbiome and identifying key molecules and molecular pathways that can be used for more targeted, individualized therapies that will restrain oral inflammation and restore periodontal tissue homeostasis. This book introduces novel concepts and molecules that are currently being tested in preclinical and clinical models. Readers will find detailed information from leading experts on specific therapeutic strategies targeting the host immune and inflammatory system, the oral microbiome, and regeneration.

Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer.

This tool for veterinary professionals offers current information about alternative medical treatments, primarily for dogs and cats. Chapters begin with the basics and background followed by sample protocols. The main part lists neutraceutical supplements and botanicals, covering actions, use, contraindications, adverse effects, potential interactions, dose, and sources. Materials are listed by common name, with Latin names provided. Appendix lists numerous resources.

This book reports on the latest technological and clinical advances in the field of neurorehabilitation. It is, however, much more than a conventional survey of the state-of-the-art in neurorehabilitation technologies and therapies. It was formed on the basis of a week of lively discussions between curious PhD students and leading research experts during the summer school on neurorehabilitation (SSNR2012), September 16-21 in Nuévalos, Zaragoza (Spain). Its unconventional format makes it a perfect guide for all PhD students, researchers and professionals interested in gaining a multidisciplinary perspective on current and future neurorehabilitation scenarios. The book covers various aspects of neurorehabilitation research and practice, organized into different parts. The first part discusses a selection of common impairments affecting brain function, such as stroke, cerebral palsy and Parkinson’s disease; the second deals with both spinal cord and brain plasticity. The third part covers the most recent rehabilitation and diagnostics technologies, including robotics, neuroprostheses, brain-machine interfaces and electromyography systems. Practical examples and case studies related to the application of some of the latest techniques in realistic clinical scenarios are covered in the fourth part.

This book provides a comprehensive, state-of-the art review of current and new therapies in treating pancreatic cancer. In addition to discussing the current landscape for treating various stages of pancreatic cancer, the text highlights several standard and emerging approaches, with a particular emphasis on novel endoscopic, surgical, chemotherapeutic, radiotherapeutic, targeted, and immunotherapeutic strategies. The volume also features concepts on the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer. Written by experts from a variety of integrative disciplines, Current and Emerging Therapies in Pancreatic Cancer is a valuable resource for oncologists, gastroenterologists, surgeons, and other professionals who treat and manage patients with pancreatic cancer.

This volume provides readers with the most updated scientific information on the efficacy and safety of medicines for children and adolescents. The book enriches the understanding of pediatric pharmacotherapy for health professionals, regulatory agencies, pharmaceutical companies and learned societies. It contains important information on the pharmacodynamics and pharmacokinetics of drugs. It summarizes the latest investigations on the effects of pharmacological treatments in relation to and dependent on age, gender, fat mass and disease status. Therefore and importantly, this volume reviews the latest data on how pharmacotherapy has to be adjusted and personalized in regards to stages of development and during the pediatric lifespan from neonate through adolescence. In addition, the topic of rare diseases and special challenges for pharmacotherapy will be included and will provide readers with the necessary knowledge to handle complex diseases and treatment strategies especially in relation to pharmacotherapy of rare and orphan diseases.

This comprehensive and critical review of current and established treatment modalities for malignant liver tumors is designed to help you sort through the proliferation of competitive approaches and choose the best treatment options for your patient. Dr. Clavien and his contributors consider all the options – radiological, surgical, pharmaceutical, and emerging/novel therapies – and help you find the best single or combined therapy. Building on the success of the previous edition, this extremely thorough revision: features a new section on Guidelines for Liver Tumors, where you will find specific strategies for treating common liver malignancies; the guidelines were prepared by the Associate Editors and take into account national and international society guidelines reflects actual practice by taking a multidisciplinary approach, with contributions from international experts who have extensive experience with this patient population achieves comprehensive and balanced coverage by having each chapter reviewed by the Editor, Deputy Editor, two Associate Editors, and at least one external reviewer includes 16 new chapters that cover liver anatomy, histologic changes in the liver, epidemiology and natural history of HCC, CCC and colorectal liver metastases, strategies of liver resection, and economic aspects as well as novel therapies facilitates the kind of daily interaction among hepatologists, hepatic surgeons, medical oncologists, radiotherapists, and interventional radiologists that is essential when treating patients with complex liver malignancies In 44 chapters organized into six major sections, the book covers the full range of liver tumors. The perfect blend of evidence and experience, Malignant Liver Tumors: Current and Emerging Therapies, 3rd Edition, illuminates the path to better patient care.